Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age

Megan Allyse, L. C. Sayres, T. A. Goodspeed, M. K. Cho

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To determine how adults in the United States view non-invasive prenatal testing using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake.Study Design: A national sample of 1861 US-based adults was surveyed using a validated online survey instrument. The survey was administered by a commercial survey research company. Respondents were randomized to receive a survey about prenatal testing for trisomy 13 and 18 or trisomy 21. Participants were asked to select among testing modalities, including cffDNA testing, and rank the features of testing that they considered most important to decision making. Result: There was substantive interest in the use of cffDNA testing rather than traditional screening mechanisms, with a minority of respondents reporting that they would support the use of both methods in combination. The lower rates of false-negative and false-positive test results and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Participants expressed strong support for diagnostic confirmation via invasive testing after a positive result from either screening or cffDNA testing. However, almost one-third of participants reported that they would not endorse the use of either invasive or non-invasive prenatal testing. Conclusion: There appears to be support for uptake of non-invasive prenatal tests. Clinical guidelines should therefore go forward in providing guidance on how to integrate non-invasive methods into the current standard of care. However, our findings indicate that even when accuracy, which is rated by patients as the most important aspect of prenatal testing, is significantly improved over existing screening methods and testing is offered non-invasively, the number of individuals who reported that they would decline any testing remained the same. Attention should therefore be directed at ensuring that the right of informed refusal of prenatal testing is not impacted by new, non-invasive methods.

Original languageEnglish (US)
Pages (from-to)429-434
Number of pages6
JournalJournal of Perinatology
Volume34
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Aneuploidy
Aptitude
Standard of Care
Down Syndrome
Surveys and Questionnaires
Decision Making
Guidelines
Pregnancy
DNA
Research

Keywords

  • ethics
  • prenatal diagnosis
  • prenatal testing

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. / Allyse, Megan; Sayres, L. C.; Goodspeed, T. A.; Cho, M. K.

In: Journal of Perinatology, Vol. 34, No. 6, 01.01.2014, p. 429-434.

Research output: Contribution to journalArticle

Allyse, Megan ; Sayres, L. C. ; Goodspeed, T. A. ; Cho, M. K. / Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. In: Journal of Perinatology. 2014 ; Vol. 34, No. 6. pp. 429-434.
@article{eec3dcc4faf144e995ed7f7dee7b63b1,
title = "Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age",
abstract = "Objective: To determine how adults in the United States view non-invasive prenatal testing using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake.Study Design: A national sample of 1861 US-based adults was surveyed using a validated online survey instrument. The survey was administered by a commercial survey research company. Respondents were randomized to receive a survey about prenatal testing for trisomy 13 and 18 or trisomy 21. Participants were asked to select among testing modalities, including cffDNA testing, and rank the features of testing that they considered most important to decision making. Result: There was substantive interest in the use of cffDNA testing rather than traditional screening mechanisms, with a minority of respondents reporting that they would support the use of both methods in combination. The lower rates of false-negative and false-positive test results and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Participants expressed strong support for diagnostic confirmation via invasive testing after a positive result from either screening or cffDNA testing. However, almost one-third of participants reported that they would not endorse the use of either invasive or non-invasive prenatal testing. Conclusion: There appears to be support for uptake of non-invasive prenatal tests. Clinical guidelines should therefore go forward in providing guidance on how to integrate non-invasive methods into the current standard of care. However, our findings indicate that even when accuracy, which is rated by patients as the most important aspect of prenatal testing, is significantly improved over existing screening methods and testing is offered non-invasively, the number of individuals who reported that they would decline any testing remained the same. Attention should therefore be directed at ensuring that the right of informed refusal of prenatal testing is not impacted by new, non-invasive methods.",
keywords = "ethics, prenatal diagnosis, prenatal testing",
author = "Megan Allyse and Sayres, {L. C.} and Goodspeed, {T. A.} and Cho, {M. K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/jp.2014.30",
language = "English (US)",
volume = "34",
pages = "429--434",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age

AU - Allyse, Megan

AU - Sayres, L. C.

AU - Goodspeed, T. A.

AU - Cho, M. K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: To determine how adults in the United States view non-invasive prenatal testing using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake.Study Design: A national sample of 1861 US-based adults was surveyed using a validated online survey instrument. The survey was administered by a commercial survey research company. Respondents were randomized to receive a survey about prenatal testing for trisomy 13 and 18 or trisomy 21. Participants were asked to select among testing modalities, including cffDNA testing, and rank the features of testing that they considered most important to decision making. Result: There was substantive interest in the use of cffDNA testing rather than traditional screening mechanisms, with a minority of respondents reporting that they would support the use of both methods in combination. The lower rates of false-negative and false-positive test results and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Participants expressed strong support for diagnostic confirmation via invasive testing after a positive result from either screening or cffDNA testing. However, almost one-third of participants reported that they would not endorse the use of either invasive or non-invasive prenatal testing. Conclusion: There appears to be support for uptake of non-invasive prenatal tests. Clinical guidelines should therefore go forward in providing guidance on how to integrate non-invasive methods into the current standard of care. However, our findings indicate that even when accuracy, which is rated by patients as the most important aspect of prenatal testing, is significantly improved over existing screening methods and testing is offered non-invasively, the number of individuals who reported that they would decline any testing remained the same. Attention should therefore be directed at ensuring that the right of informed refusal of prenatal testing is not impacted by new, non-invasive methods.

AB - Objective: To determine how adults in the United States view non-invasive prenatal testing using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake.Study Design: A national sample of 1861 US-based adults was surveyed using a validated online survey instrument. The survey was administered by a commercial survey research company. Respondents were randomized to receive a survey about prenatal testing for trisomy 13 and 18 or trisomy 21. Participants were asked to select among testing modalities, including cffDNA testing, and rank the features of testing that they considered most important to decision making. Result: There was substantive interest in the use of cffDNA testing rather than traditional screening mechanisms, with a minority of respondents reporting that they would support the use of both methods in combination. The lower rates of false-negative and false-positive test results and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Participants expressed strong support for diagnostic confirmation via invasive testing after a positive result from either screening or cffDNA testing. However, almost one-third of participants reported that they would not endorse the use of either invasive or non-invasive prenatal testing. Conclusion: There appears to be support for uptake of non-invasive prenatal tests. Clinical guidelines should therefore go forward in providing guidance on how to integrate non-invasive methods into the current standard of care. However, our findings indicate that even when accuracy, which is rated by patients as the most important aspect of prenatal testing, is significantly improved over existing screening methods and testing is offered non-invasively, the number of individuals who reported that they would decline any testing remained the same. Attention should therefore be directed at ensuring that the right of informed refusal of prenatal testing is not impacted by new, non-invasive methods.

KW - ethics

KW - prenatal diagnosis

KW - prenatal testing

UR - http://www.scopus.com/inward/record.url?scp=84901779176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901779176&partnerID=8YFLogxK

U2 - 10.1038/jp.2014.30

DO - 10.1038/jp.2014.30

M3 - Article

VL - 34

SP - 429

EP - 434

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 6

ER -